08:00 , Mar 24, 2003 |  BioCentury  |  Politics, Policy & Law

Slippery slope for patient advocates

As patient advocacy groups have proliferated, the intensified competition for funding has led some patient organizations to aggressively solicit funding from drug companies, sometimes using offers of special access to members or other inducements to...
07:00 , Jun 28, 1999 |  BioCentury  |  Finance

It's all a matter of time

As everyone knows, the real issue in biotech investing is how long it takes to make any money. Two recent high-profile take-outs - Abbott's $7.3 billion stock buyout of Alza (AZA) announced last week, and...
07:00 , Aug 11, 1997 |  BioCentury  |  Emerging Company Profile

Acacia Biosciences Inc.

Acacia Biosciences Inc. Richmond, Calif. Technology: Genome Reporter Matrix yeast-based assay using genetic and chemical response profiles to assess a compound's effects over multiple disease pathways Disease focus: N/A Clinical status: N/A Founded: 1995 by...
07:00 , Aug 11, 1997 |  BioCentury  |  Emerging Company Profile

Acacia: A model organism in yeast

Emerging Company Profile In 1996, the 6,000 genes in the yeast genome (Saccharomyces cerevisiae) were sequenced. The majority of these genes have human counterparts, and the majority of metabolic and signaling pathways are directly or...